

Allison W Kurian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5351490/publications.pdf>

Version: 2024-02-01

313
papers

13,297
citations

20759

60
h-index

28224

105
g-index

318
all docs

318
docs citations

318
times ranked

15314
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	2.3	498
2	Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLoS ONE, 2012, 7, e33788.	1.1	475
3	Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. Journal of Clinical Oncology, 2014, 32, 2001-2009.	0.8	442
4	A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 2021, 384, 440-451.	13.9	414
5	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 9-20.	2.3	408
6	Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 619-626.	1.1	341
7	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	2.3	314
8	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncology, 2015, 1, 943.	3.4	294
9	Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. Journal of Clinical Oncology, 2019, 37, 1305-1315.	0.8	266
10	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	2.3	253
11	Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA - Journal of the American Medical Association, 2006, 295, 2374.	3.8	240
12	Use of and Mortality After Bilateral Mastectomy Compared With Other Surgical Treatments for Breast Cancer in California, 1998-2011. JAMA - Journal of the American Medical Association, 2014, 312, 902.	3.8	221
13	Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers. Journal of Clinical Oncology, 2010, 28, 222-231.	0.8	217
14	Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2017, 35, 2232-2239.	0.8	212
15	Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA - Journal of the American Medical Association, 2018, 319, 154.	3.8	209
16	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Journal of Clinical Oncology, 2015, 33, 1895-1901.	0.8	200
17	Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectrum, 2018, 2, pky062.	1.4	199
18	Age-Specific Incidence of Breast Cancer Subtypes: Understanding the Black-White Crossover. Journal of the National Cancer Institute, 2012, 104, 1094-1101.	3.0	197

#	ARTICLE	IF	CITATIONS
19	Occurrence of breast cancer subtypes in adolescent and young adult women. <i>Breast Cancer Research</i> , 2012, 14, R55.	2.2	196
20	Genetic insights into biological mechanisms governing human ovarian ageing. <i>Nature</i> , 2021, 596, 393-397.	13.7	183
21	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. <i>Current Opinion in Obstetrics and Gynecology</i> , 2010, 22, 72-78.	0.9	170
22	A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 533-544.	1.2	167
23	CDH1 Truncating Mutations in the E-Cadherin Gene. <i>Annals of Surgery</i> , 2007, 245, 873-879.	2.1	157
24	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 153-162.	2.3	153
25	Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1066.	3.4	146
26	Histologic types of epithelial ovarian cancer: have they different risk factors?. <i>Gynecologic Oncology</i> , 2005, 96, 520-530.	0.6	143
27	Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 471-478.	1.1	140
28	Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. <i>Breast Cancer Research</i> , 2010, 12, R99.	2.2	139
29	Biomedical terahertz imaging with a quantum cascade laser. <i>Applied Physics Letters</i> , 2006, 88, 153903.	1.5	133
30	Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. <i>Genetics in Medicine</i> , 2018, 20, 234-239.	1.1	131
31	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1326-1338.	2.3	119
32	Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. <i>Cancer</i> , 2018, 124, 3668-3676.	2.0	118
33	A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 634-641.	0.8	115
34	Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1058-1065.	3.0	114
35	Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer. <i>JAMA Surgery</i> , 2017, 152, 274.	2.2	107
36	Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 531.	3.8	103

#	ARTICLE	IF	CITATIONS
37	Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. <i>Radiology</i> , 2018, 288, 26-35.	3.6	102
38	Trends in Reoperation After Initial Lumpectomy for Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1352.	3.4	100
39	Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	96
40	Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1039-1045.	1.1	95
41	Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. <i>PLoS ONE</i> , 2012, 7, e43994.	1.1	93
42	Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. <i>Radiology</i> , 2017, 285, 401-413.	3.6	92
43	Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1484-1494.	3.0	92
44	The California Breast Density Information Group: A Collaborative Response to the Issues of Breast Density, Breast Cancer Risk, and Breast Density Notification Legislation. <i>Radiology</i> , 2013, 269, 887-892.	3.6	90
45	Obesity and Mortality After Breast Cancer by Race/Ethnicity: The California Breast Cancer Survivorship Consortium. <i>American Journal of Epidemiology</i> , 2014, 179, 95-111.	1.6	90
46	Concerns About Cancer Risk and Experiences With Genetic Testing in a Diverse Population of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1584-1591.	0.8	88
47	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. <i>Nature Communications</i> , 2020, 11, 3833.	5.8	88
48	A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 2594-2598.	0.7	84
49	Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. <i>Journal of Medical Genetics</i> , 2016, 53, 15-23.	1.5	82
50	Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2012, 30, 497-506.	0.8	81
51	Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. <i>Journal of the National Cancer Institute</i> , 2019, 111, 95-98.	3.0	81
52	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016, 115, 129-135.	2.9	80
53	Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways. <i>Clinical Cancer Research</i> , 2017, 23, 3334-3342.	3.2	80
54	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. <i>JAMA Network Open</i> , 2020, 3, e208501.	2.8	79

#	ARTICLE	IF	CITATIONS
55	Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. <i>Cancer</i> , 2004, 100, 479-489.	2.0	77
56	Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e2019452.	2.8	76
57	Multigene Panel Testing in Oncology Practice. <i>JAMA Oncology</i> , 2015, 1, 277.	3.4	68
58	Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. <i>Cancer</i> , 2017, 123, 1925-1934.	2.0	68
59	Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (<i>ATM</i>) Gene are Associated with High and Moderate Risks for Multiple Cancers. <i>Cancer Prevention Research</i> , 2021, 14, 433-440.	0.7	68
60	Performance of Prediction Models for BRCA Mutation Carriage in Three Racial/Ethnic Groups: Findings from the Northern California Breast Cancer Family Registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1084-1091.	1.1	66
61	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2851-2858.	3.2	65
62	Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. <i>Familial Cancer</i> , 2008, 7, 179-186.	0.9	63
63	Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 361-368.	1.1	62
64	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. <i>Journal of Clinical Oncology</i> , 2021, 39, 1631-1640.	0.8	62
65	Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1218-1224.	0.8	59
66	Performance of BRCA1/2 Mutation Prediction Models in Asian Americans. <i>Journal of Clinical Oncology</i> , 2008, 26, 4752-4758.	0.8	57
67	Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. <i>Clinical Cancer Research</i> , 2017, 23, 3365-3370.	3.2	55
68	Tobacco Smoking and Risk of Second Primary Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 968-979.	0.5	54
69	Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California. <i>Journal of Clinical Oncology</i> , 2010, 28, e155-e157.	0.8	53
70	Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. <i>Journal of Community Health</i> , 2015, 40, 1287-1299.	1.9	53
71	Breast Cancer Risk Reduction, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 880-915.	2.3	52
72	Recurrence risk perception and quality of life following treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 557-565.	1.1	51

#	ARTICLE	IF	CITATIONS
73	Treatment decisions and employment of breast cancer patients: Results of a population-based survey. <i>Cancer</i> , 2017, 123, 4791-4799.	2.0	51
74	Recent Trends in Chemotherapy Use and Oncologists'™ Treatment Recommendations for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 493-500.	3.0	50
75	Racial/Ethnic and Socioeconomic Differences in Short-Term Breast Cancer Survival Among Women in an Integrated Health System. <i>American Journal of Public Health</i> , 2015, 105, 938-946.	1.5	49
76	Breast cancer treatment across health care systems: Linking electronic medical records and state registry data to enable outcomes research. <i>Cancer</i> , 2014, 120, 103-111.	2.0	48
77	Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. <i>Cancer Causes and Control</i> , 2016, 27, 1127-1138.	0.8	48
78	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
79	The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. <i>Cancer Causes and Control</i> , 2013, 24, 1821-1836.	0.8	47
80	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. <i>Nature Communications</i> , 2020, 11, 1217.	5.8	46
81	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021, 113, 329-337.	3.0	45
82	A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1066-1077.	1.1	43
83	Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	1.0	43
84	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. <i>JCO Precision Oncology</i> , 2020, 4, 585-592.	1.5	41
85	Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. <i>JAMIA Open</i> , 2019, 2, 528-537.	1.0	40
86	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	2.6	39
87	Breast Cancer Risk for Noncarriers of Family-Specific <i>BRCA1</i> and <i>BRCA2</i> Mutations: Findings From the Breast Cancer Family Registry. <i>Journal of Clinical Oncology</i> , 2011, 29, 4505-4509.	0.8	38
88	Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 247-260.	1.1	37
89	Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. <i>Medical Decision Making</i> , 2018, 38, 9S-23S.	1.2	37
90	Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. <i>Cancer Research</i> , 2018, 78, 4241-4252.	0.4	36

#	ARTICLE	IF	CITATIONS
91	Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 895-902.	1.1	36
92	Breast Cancer Screening Strategies for Women With <i>ATM</i> , <i>CHEK2</i> , and <i>PALB2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2022, 8, 587.	3.4	36
93	Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 219-228.	2.3	35
94	The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 525-535.	1.1	34
95	Patient communication of cancer genetic test results in a diverse population. <i>Translational Behavioral Medicine</i> , 2018, 8, 85-94.	1.2	34
96	Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 23-33.	0.9	33
97	Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, e196400.	3.4	32
98	How can we best respect patient autonomy in breast cancer treatment decisions?. <i>Breast Cancer Management</i> , 2015, 4, 53-64.	0.2	31
99	Multiple imputation with missing data indicators. <i>Statistical Methods in Medical Research</i> , 2021, 30, 2685-2700.	0.7	30
100	A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 389-398.	1.1	29
101	Treatment Decision Making and Genetic Testing for Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 997.	3.8	29
102	Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1282-1290.	1.1	29
103	Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors. <i>Psycho-Oncology</i> , 2022, 31, 9-20.	1.0	29
104	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1332-1341.	1.1	28
105	Ductal Lavage of Fluid-Yielding and Non-Fluid-Yielding Ducts in BRCA1 and BRCA2 Mutation Carriers and Other Women at High Inherited Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1082-1089.	1.1	27
106	Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. <i>Familial Cancer</i> , 2012, 11, 429-439.	0.9	27
107	Polygenic risk scores for prediction of breast cancer risk in Asian populations. <i>Genetics in Medicine</i> , 2022, 24, 586-600.	1.1	27
108	Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 995.	3.8	26

#	ARTICLE	IF	CITATIONS
109	The Impact of COVID-19 on Patients With Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 580-587.	0.6	26
110	The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. <i>Current Treatment Options in Oncology</i> , 2017, 18, 27.	1.3	25
111	Genetics of triple-negative breast cancer: Implications for patient care. <i>Current Problems in Cancer</i> , 2016, 40, 130-140.	1.0	24
112	Linking Electronic Health Records to Better Understand Breast Cancer Patient Pathways Within and Between Two Health Systems. <i>EGEMS (Washington, DC)</i> , 2017, 3, 5.	2.0	24
113	Beyond barriers: fundamental "disconnects" underlying the treatment of breast cancer patients' sexual health. <i>Culture, Health and Sexuality</i> , 2014, 16, 1169-1180.	1.0	23
114	Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	23
115	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
116	Second Opinions From Medical Oncologists for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 391.	3.4	22
117	Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. <i>JAMA Surgery</i> , 2018, 153, 909.	2.2	22
118	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. <i>Journal of Clinical Oncology</i> , 2021, 39, 3918-3926.	0.8	22
119	Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. <i>Cancer</i> , 2021, 127, 3742-3750.	2.0	21
120	Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. <i>Cancer</i> , 2021, 127, 1275-1285.	2.0	21
121	History of Recreational Physical Activity and Survival After Breast Cancer. <i>American Journal of Epidemiology</i> , 2015, 181, 944-955.	1.6	20
122	The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1064-1072.	1.1	20
123	Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. <i>World Journal of Surgery</i> , 2012, 36, 702-713.	0.8	19
124	A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2013, 2, 95-103.	0.7	19
125	Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 108.	2.2	19
126	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 44-56.	1.8	19

#	ARTICLE	IF	CITATIONS
127	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. <i>Value in Health</i> , 2018, 21, 1062-1068.	0.1	19
128	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	5.8	19
129	Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research. <i>AMIA ... Annual Symposium proceedings</i> , 2012, 2012, 970-8.	0.2	19
130	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. <i>Health Expectations</i> , 2005, 8, 221-233.	1.1	18
131	Patient, Hospital, and Neighborhood Factors Associated with Treatment of Early-Stage Breast Cancer among Asian American Women in California. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 821-834.	1.1	18
132	Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2018, 143, 3262-3272.	2.3	18
133	Emerging Opportunity of Cascade Genetic Testing for Population-Wide Cancer Prevention and Control. <i>Journal of Clinical Oncology</i> , 2020, 38, 1371-1374.	0.8	18
134	Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. <i>JCO Precision Oncology</i> , 2021, 5, 307-316.	1.5	18
135	Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer. <i>Cancer</i> , 2017, 123, 43-51.	2.0	17
136	Genomic landscape of ductal carcinoma in situ and association with progression. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 307-316.	1.1	17
137	Is Breast Cancer in Asian and Asian American Women a Different Disease?. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1243-1244.	3.0	17
138	The decline in breast cancer incidence: Real or imaginary?. <i>Current Oncology Reports</i> , 2009, 11, 21-28.	1.8	16
139	Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e37-e55.	1.4	16
140	Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. <i>JAMA Oncology</i> , 2021, 7, 585-592.	3.4	16
141	Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. <i>Cancer</i> , 2019, 125, 943-951.	2.0	15
142	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	2.2	15
143	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. <i>Breast Cancer Research</i> , 2022, 24, 27.	2.2	15
144	A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2007, 179, 89-92.	1.0	14

#	ARTICLE	IF	CITATIONS
145	Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 931-933.	1.1	14
146	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 72.	2.0	14
147	Patient-clinician interactions and disparities in breast cancer care: the equality in breast cancer care study. <i>Journal of Cancer Survivorship</i> , 2019, 13, 968-980.	1.5	14
148	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. <i>EBioMedicine</i> , 2019, 48, 203-211.	2.7	14
149	Automatic inference of BI-RADS final assessment categories from narrative mammography report findings. <i>Journal of Biomedical Informatics</i> , 2019, 92, 103137.	2.5	14
150	Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 469-478.	1.0	14
151	Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 662-668.	2.3	14
152	Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 475-482.	1.1	14
153	Statins may reduce breast cancer risk, particularly hormone receptor-negative disease. <i>Current Breast Cancer Reports</i> , 2009, 1, 148-156.	0.5	13
154	Validation of self-reported comorbidity status of breast cancer patients with medical records: the California Breast Cancer Survivorship Consortium (CBCSC). <i>Cancer Causes and Control</i> , 2016, 27, 391-401.	0.8	13
155	Comparing 5-Year and Lifetime Risks of Breast Cancer Using the Prospective Family Study Cohort. <i>Journal of the National Cancer Institute</i> , 2021, 113, 785-791.	3.0	13
156	Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1837-e1845.	1.4	13
157	Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. <i>Journal of Genetic Counseling</i> , 2022, 31, 130-139.	0.9	13
158	Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. <i>Journal of Oncology Practice</i> , 2016, 12, e697-e709.	2.5	12
159	Primary care provider-reported involvement in breast cancer treatment decisions. <i>Cancer</i> , 2019, 125, 1815-1822.	2.0	12
160	Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 1012-1017.	1.3	12
161	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 44-56.	1.8	12
162	Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. <i>Familial Cancer</i> , 2013, 12, 65-73.	0.9	11

#	ARTICLE	IF	CITATIONS
163	Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. <i>Cancer</i> , 2020, 126, 958-970.	2.0	11
164	Weakly supervised temporal model for prediction of breast cancer distant recurrence. <i>Scientific Reports</i> , 2021, 11, 9461.	1.6	11
165	Dynamic strategy for personalized medicine: An application to metastatic breast cancer. <i>Journal of Biomedical Informatics</i> , 2017, 68, 50-57.	2.5	10
166	Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1237-1245.	0.4	10
167	Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1069-1069.	0.8	10
168	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. <i>Cancers</i> , 2022, 14, 2716.	1.7	10
169	Synergistic drug combinations from electronic health records and gene expression. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 565-576.	2.2	9
170	Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California. <i>American Journal of Clinical Pathology</i> , 2017, 148, 199-207.	0.4	9
171	Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012. <i>Annals of Surgery</i> , 2017, 266, 353-360.	2.1	9
172	Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-8.	1.5	9
173	Rapid detection of <i>BRCA1/2</i> recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. <i>Oncotarget</i> , 2018, 9, 7832-7843.	0.8	9
174	Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. <i>Value in Health</i> , 2020, 23, 551-558.	0.1	9
175	Comprehensive Breast Cancer Risk Assessment for <i>CHEK2</i> and <i>ATM</i> Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. <i>JCO Precision Oncology</i> , 2021, 5, 1073-1081.	1.5	9
176	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	2.9	9
177	Development of a Mobile Health App (TOGETHERCare) to Reduce Cancer Care Partner Burden: Product Design Study. <i>JMIR Formative Research</i> , 2021, 5, e22608.	0.7	9
178	Precision Medicine in Breast Cancer Care. <i>JAMA Oncology</i> , 2015, 1, 1109.	3.4	8
179	The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 587-595.	1.1	8
180	What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment?. <i>Medical Decision Making</i> , 2018, 38, 95-106.	1.2	8

#	ARTICLE	IF	CITATIONS
181	Oncologistsâ€™ influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 751-756.	1.1	7
182	Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?. <i>JCO Precision Oncology</i> , 2018, 2, 1-10.	1.5	7
183	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	2.2	7
184	Development and Validation of a Simulation Modelâ€“Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. <i>Journal of Clinical Oncology</i> , 2021, 39, 2893-2902.	0.8	7
185	Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 351-363.	1.1	7
186	Racial/ethnic differences in cancer diagnosed after metastasis: absolute burden and deaths potentially avoidable through earlier detection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0823.2021.	1.1	7
187	Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial. <i>Cancer</i> , 2018, 124, 4000-4009.	2.0	6
188	Chromatin Remodeling in Response to BRCA2-Crisis. <i>Cell Reports</i> , 2019, 28, 2182-2193.e6.	2.9	6
189	Hospital Characteristics and Breast Cancer Survival in the California Breast Cancer Survivorship Consortium. <i>JCO Oncology Practice</i> , 2020, 16, e517-e528.	1.4	6
190	Health Disparities in Germline Genetic Testing for Cancer Susceptibility. <i>Current Breast Cancer Reports</i> , 2020, 12, 51-58.	0.5	6
191	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	2.6	6
192	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	2.0	6
193	Ductal Pattern Enhancement on Magnetic Resonance Imaging of the Breast Due to Ductal Lavage. <i>Breast Journal</i> , 2007, 13, 281-286.	0.4	5
194	High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 605-607.	1.1	5
195	Information Technology Interventions to Improve Cancer Care Quality: A Report From the American Society of Clinical Oncology Quality Care Symposium. <i>Journal of Oncology Practice</i> , 2013, 9, 142-144.	2.5	5
196	Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988â€“2013. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 333-338.	1.1	5
197	Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies. <i>PLoS ONE</i> , 2018, 13, e0195666.	1.1	5
198	A case of a transâ€™masculine patient receiving testosterone with a history of estrogen receptorâ€™positive breast cancer. <i>Breast Journal</i> , 2020, 26, 1888-1889.	0.4	5

#	ARTICLE	IF	CITATIONS
199	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	2.9	5
200	Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 600-614.	1.0	5
201	Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 245-253.	3.0	5
202	Magnetic Resonance Galactography: a Feasibility Study in Women with Prior Atypical Breast Duct Cytology. <i>Breast Journal</i> , 2008, 14, 211-214.	0.4	4
203	Navigating choices when applying multiple imputation in the presence of multi-level categorical interaction effects. <i>Statistical Methodology</i> , 2015, 27, 82-99.	0.5	4
204	Patterns of social media use and associations with psychosocial outcomes among breast and gynecologic cancer survivors. <i>Journal of Cancer Survivorship</i> , 2021, 15, 677-684.	1.5	4
205	Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). <i>Cancer Prevention Research</i> , 2022, 15, 185-191.	0.7	4
206	Association of illness mindsets with health-related quality of life in cancer survivors.. <i>Health Psychology</i> , 2022, 41, 389-395.	1.3	4
207	A Young Woman With Bilateral Breast Cancer: Identifying a Genetic Cause and Implications for Management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 512-517.	2.3	3
208	Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1173-1185.	0.6	3
209	Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa083.	1.4	3
210	Benchmark Method for Cost Computations Across Health Care Systems: Cost of Care per Patient per Day in Breast Cancer Care. <i>JCO Oncology Practice</i> , 2021, 17, e1403-e1412.	1.4	3
211	Receipt of guideline-concordant care among young adult women with breast cancer. <i>Cancer</i> , 2021, 127, 3325-3333.	2.0	3
212	Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5510-5510.	0.8	3
213	Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1008-1008.	0.8	3
214	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz062.	1.4	2
215	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	1.6	2
216	Widening cancer care disparities in the adoption of telemedicine during COVID 19: who is left behind?. <i>Gynecologic Oncology</i> , 2021, 162, S23.	0.6	2

#	ARTICLE	IF	CITATIONS
217	Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1479-1489.	0.5	2
218	Abstract P3-07-01: Breast cancer-specific mortality (BCSM) in patients age 50 years or younger with node-positive (N+) breast cancer (BC) treated based on the 21-gene assay in clinical practice. <i>Cancer Research</i> , 2020, 80, P3-07-01-P3-07-01.	0.4	2
219	Genetic testing decisions of breast cancer patients: Results from the iCanCare study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1541-1541.	0.8	2
220	Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 560-560.	0.8	2
221	Performance of the IBIS/Tyrer-Cuzick (TC) Model by race/ethnicity in the Womenâ€™s Health Initiative.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1503-1503.	0.8	2
222	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	1.6	2
223	Statin use and all-cancer mortality: Prospective results from the Womenâ€™s Health Initiative.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1506-1506.	0.8	2
224	Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients: Knowledge and physician influence.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1011-1011.	0.8	2
225	Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline <i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> pathogenic variants.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1549-1549.	0.8	2
226	Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes. <i>JCO Precision Oncology</i> , 2021, 5, 1853-1859.	1.5	2
227	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics. <i>Cancer Medicine</i> , 2022, 11, 297-307.	1.3	2
228	Reply to D.G. Evans et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 1143-1144.	0.8	1
229	Genetic Polymorphisms as Predictors of Breast Cancer Risk. <i>Current Breast Cancer Reports</i> , 2012, 4, 232-239.	0.5	1
230	Multiple-Gene Panels and the Future of Genetic Testing. <i>Current Breast Cancer Reports</i> , 2015, 7, 98-104.	0.5	1
231	Addressing inherited predisposition for breast cancer in transplant recipients. <i>Journal of Surgical Oncology</i> , 2016, 113, 605-608.	0.8	1
232	Reply to Comment on â€˜Statin use and all-cancer survival: prospective results from the Womenâ€™s Health Initiativeâ€™. <i>British Journal of Cancer</i> , 2017, 116, e2-e2.	2.9	1
233	Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancerâ€™Reply. <i>JAMA Oncology</i> , 2018, 4, 1788.	3.4	1
234	Multicancer hereditary syndrome testing: Genetic counselorsâ€™ perspectives.. <i>Journal of Clinical Oncology</i> , 2021, 39, 106-106.	0.8	1

#	ARTICLE	IF	CITATIONS
235	Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.. Journal of Clinical Oncology, 2015, 33, 1513-1513.	0.8	1
236	Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial.. Journal of Clinical Oncology, 2016, 34, 1503-1503.	0.8	1
237	Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?. Journal of Clinical Oncology, 2017, 35, 1528-1528.	0.8	1
238	Unmet need for clinician engagement about financial toxicity after diagnosis of breast cancer.. Journal of Clinical Oncology, 2018, 36, 10080-10080.	0.8	1
239	Computing the cost of care per day of breast cancer survivor care.. Journal of Clinical Oncology, 2018, 36, 10-10.	0.8	1
240	Preventive surgery after multiplex genetic panel testing (MGPT).. Journal of Clinical Oncology, 2019, 37, 1525-1525.	0.8	1
241	Oncotype DX DCIS use and clinical utility: A SEER population-based study.. Journal of Clinical Oncology, 2019, 37, e12046-e12046.	0.8	1
242	Recurrence risk perception and quality of life after treatment of breast cancer.. Journal of Clinical Oncology, 2016, 34, 175-175.	0.8	1
243	Breast oncology precision medicine: Genomic testing and treatment at the population level.. Journal of Clinical Oncology, 2016, 34, 288-288.	0.8	1
244	Gaps in integrating genetic testing into management of breast cancer.. Journal of Clinical Oncology, 2017, 35, 160-160.	0.8	1
245	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. Journal of Clinical Oncology, 2019, 37, 6531-6531.	0.8	1
246	Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site.. Journal of Clinical Oncology, 2020, 38, 2043-2043.	0.8	1
247	Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations. JNCI Cancer Spectrum, 2022, 6, .	1.4	1
248	Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 379-386.e9.	2.3	1
249	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. JNCI Cancer Spectrum, 2021, 5, pkab090.	1.4	1
250	Relevance of the MHC region for breast cancer susceptibility in Asians. Breast Cancer, 2022, 29, 869-879.	1.3	1
251	A case-control study of healthcare disparities in sex and gender minority patients with breast cancer.. Journal of Clinical Oncology, 2022, 40, 6517-6517.	0.8	1
252	Association of germline genetic testing results with chemotherapy regimens received by women with early-stage breast cancer.. Journal of Clinical Oncology, 2022, 40, 10518-10518.	0.8	1

#	ARTICLE	IF	CITATIONS
253	Constitutional <i>BRCA1</i> methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10509-10509.	0.8	1
254	Symptoms and survivorship needs differences between "good sleepers" and "bad sleepers" in survivors of breast and gynecologic cancers. <i>Sleep Medicine</i> , 2022, 100, 49-55.	0.8	1
255	Comparative Analysis of Bio-Medical Imaging at 3.7 Terahertz with a High Power Quantum Cascade Laser. , 2006, , .		0
256	Reply to S.M. Sorscher and A.B. Hafeez Bhatti. <i>Journal of Clinical Oncology</i> , 2015, 33, 4233-4233.	0.8	0
257	Response to Peshkin, Isaacs, and Schwartz. <i>Journal of the National Cancer Institute</i> , 2019, 111, 874-874.	3.0	0
258	Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?. <i>Personalized Medicine</i> , 2019, 16, 365-367.	0.8	0
259	Guidelines Do Not Proscribe Surgeons Performing Genetic Testing"Reply. <i>JAMA Surgery</i> , 2019, 154, 269.	2.2	0
260	Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 397.	3.8	0
261	Financing of germline testing: implications for availability and access. <i>Molecular Genetics and Metabolism</i> , 2021, 132, S330-S331.	0.5	0
262	Multicancer hereditary syndrome testing: Genetic counselors'™ perspectives.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10594-10594.	0.8	0
263	Cancer-specific mortality associated with germline genetic testing results among women with breast cancer or ovarian cancer treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10517-10517.	0.8	0
264	Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10531-10531.	0.8	0
265	Impact of disruptions in breast cancer control due to the COVID-19 pandemic on breast cancer mortality in the United States: Estimates from collaborative simulation modeling.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6562-6562.	0.8	0
266	Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10500-10500.	0.8	0
267	A simulation model-based clinical decision tool to guide personalized treatment based on individual characteristics: Does 21-gene recurrence score assay testing change decisions?. <i>Journal of Clinical Oncology</i> , 2021, 39, e12507-e12507.	0.8	0
268	Reply to Ritzwoller et al. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1026-1027.	1.0	0
269	Identification and Management of Women at High Familial Risk for Breast Cancer. , 2010, , 135-145.		0
270	Use of the 21-gene recurrence score assay (RS) and chemotherapy (CT) across health care (HC) systems.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6580-6580.	0.8	0

#	ARTICLE	IF	CITATIONS
271	Chromosomal copy number alterations (CNAs) for risk assessment of ductal carcinoma in situ (DCIS).. Journal of Clinical Oncology, 2014, 32, 565-565.	0.8	0
272	Addressing lack of US insurance coverage of Cancer Hereditary Multiplex Testing (CHMT).. Journal of Clinical Oncology, 2015, 33, e17515-e17515.	0.8	0
273	Prevalence and consequences of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.. Journal of Clinical Oncology, 2015, 33, 6508-6508.	0.8	0
274	Prevalence and predictors of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.. Journal of Clinical Oncology, 2016, 34, 185-185.	0.8	0
275	Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients.. Journal of Clinical Oncology, 2016, 34, 177-177.	0.8	0
276	Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, 1010-1010.	0.8	0
277	Compliance with guidelines and factors associated with ordering the 21-gene breast cancer assay.. Journal of Clinical Oncology, 2016, 34, 6552-6552.	0.8	0
278	Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012.. Journal of Clinical Oncology, 2016, 34, 1052-1052.	0.8	0
279	Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer.. Journal of Clinical Oncology, 2016, 34, 6501-6501.	0.8	0
280	Yield of multiplex panel testing compared to expert opinion and validated prediction models.. Journal of Clinical Oncology, 2016, 34, 1509-1509.	0.8	0
281	Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.. Journal of Clinical Oncology, 2016, 34, 1512-1512.	0.8	0
282	Dissemination of 21-gene assay testing among female breast cancer patients in the US.. Journal of Clinical Oncology, 2016, 34, 6553-6553.	0.8	0
283	Determinants of Patient Choice of Health Care Providers for Breast Cancer Treatment. Journal of Patient-centered Research and Reviews, 2016, 3, 174-175.	0.6	0
284	Recent time trends in chemotherapy use and oncologists' chemotherapy recommendations for early-stage, hormone receptor-positive breast cancer.. Journal of Clinical Oncology, 2017, 35, 541-541.	0.8	0
285	Factors associated with 21-gene assay receipt among women with lymph node positive breast cancer.. Journal of Clinical Oncology, 2017, 35, 6554-6554.	0.8	0
286	Treatment decisions and employment of breast cancer patients: Results of a population-based survey.. Journal of Clinical Oncology, 2017, 35, 10052-10052.	0.8	0
287	Expanded yield of multiplex panel testing in fully accrued prospective trial.. Journal of Clinical Oncology, 2017, 35, 1525-1525.	0.8	0
288	Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.. Journal of Clinical Oncology, 2017, 35, 1523-1523.	0.8	0

#	ARTICLE	IF	CITATIONS
289	Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.. Journal of Clinical Oncology, 2017, 35, 1576-1576.	0.8	0
290	Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling.. Journal of Clinical Oncology, 2018, 36, 1582-1582.	0.8	0
291	Genetic testing and results in population-based breast cancer patients and ovarian cancer patients.. Journal of Clinical Oncology, 2018, 36, 1578-1578.	0.8	0
292	Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling.. Journal of Clinical Oncology, 2018, 36, 1581-1581.	0.8	0
293	Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women's Health Initiative.. Journal of Clinical Oncology, 2019, 37, 1513-1513.	0.8	0
294	Radiomics features to identify distinct subtypes of triple-negative breast cancers.. Journal of Clinical Oncology, 2019, 37, 3069-3069.	0.8	0
295	Differences among Asian/Asian American, and Caucasian breast and gynecologic cancer patient-reported survivorship needs, symptoms, and illness mindsets (N=220).. Journal of Clinical Oncology, 2019, 37, 11620-11620.	0.8	0
296	Adherence to breast cancer treatment guidelines according to pathogenic variants in cancer susceptibility genes in a population-based cohort.. Journal of Clinical Oncology, 2019, 37, 34-34.	0.8	0
297	Abstract P6-08-02: 21-gene recurrence score results according to germline pathogenic variants inBRCA1, BRCA2, PALB2, ATM, CHEK2and Lynch Syndrome genes. , 2020, , .		0
298	Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.. Journal of Clinical Oncology, 2020, 38, 7063-7063.	0.8	0
299	Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model.. Journal of Clinical Oncology, 2020, 38, 1504-1504.	0.8	0
300	Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (OIs).. Journal of Clinical Oncology, 2020, 38, e19314-e19314.	0.8	0
301	Abstract IA50: Genetic testing, treatment and mortality after diagnosis of breast cancer or ovarian cancer: The SEER-GeneLINK Initiative. , 2020, , .		0
302	Abstract 2033: Reducing cancer caregiver burden: A user-centered design approach for an mHealth app. , 2020, , .		0
303	Reply to Residual confounding threatens the validity of observational studies on breast cancer local therapy. Cancer, 2020, 126, 2317-2318.	2.0	0
304	Abstract P5-03-02: Cancer risks associated with pathogenic variants in the ataxia telangiectasia mutated (ATM) gene. , 2020, , .		0
305	Abstract P6-08-07: Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations. , 2020, , .		0
306	Trends in germline genetic testing and results into survivorship for women diagnosed with breast cancer or ovarian cancer, 2013 to 2017.. Journal of Clinical Oncology, 2020, 38, 273-273.	0.8	0

#	ARTICLE	IF	CITATIONS
307	Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model. <i>Cancer Research</i> , 2022, 82, P2-11-21-P2-11-21.	0.4	0
308	Harnessing artificial intelligence to automate delineation of volumetric breast cancers from magnetic resonance imaging to improve tumor characterization.. <i>Journal of Clinical Oncology</i> , 2022, 40, 597-597.	0.8	0
309	Simulation modeling as a tool to support clinical guidelines and care for breast cancer prevention and early detection in high-risk women.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10525-10525.	0.8	0
310	National claims data analysis of outcomes of hospitalized cancer patients without COVID-19 infection during versus prior to the COVID-19 pandemic.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18679-e18679.	0.8	0
311	Radiomic features quantifying pixel-level characteristics of breast tumors from magnetic resonance imaging predict risk factors in triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12612-e12612.	0.8	0
312	A pilot study to increase cascade genetic testing in families with hereditary cancer syndromes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10602-10602.	0.8	0
313	Ancestry-specific risk of triple-negative breast cancer (TNBC) associated with germline pathogenic variants (PV) in hereditary cancer (CA) predisposition genes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10517-10517.	0.8	0